MA30041B1 - Immunoglobulines - Google Patents

Immunoglobulines

Info

Publication number
MA30041B1
MA30041B1 MA31018A MA31018A MA30041B1 MA 30041 B1 MA30041 B1 MA 30041B1 MA 31018 A MA31018 A MA 31018A MA 31018 A MA31018 A MA 31018A MA 30041 B1 MA30041 B1 MA 30041B1
Authority
MA
Morocco
Prior art keywords
immunoglobulin
antibodies
prophylaxis
disorders
treatment
Prior art date
Application number
MA31018A
Other languages
English (en)
Inventor
Stephanie Jane Clegg
Jonathan Henry Ellis
Volker Germaschewski
Paul Andrew Hamblin
George Kopsidas
Ruth Mcadam
Rabinder Kumar Prinjha
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35736284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30041(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA30041B1 publication Critical patent/MA30041B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des anticorps contre NOGO, des formulations pharmaceutiques contenant ceux-ci et l'utilisation de tels anticorps dans le traitement et/ou la prophylaxie de maladies/troubles neurologiques.
MA31018A 2005-12-16 2008-06-11 Immunoglobulines MA30041B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0525662.3A GB0525662D0 (en) 2005-12-16 2005-12-16 Immunoglobulins

Publications (1)

Publication Number Publication Date
MA30041B1 true MA30041B1 (fr) 2008-12-01

Family

ID=35736284

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31018A MA30041B1 (fr) 2005-12-16 2008-06-11 Immunoglobulines

Country Status (30)

Country Link
US (2) US8362208B2 (fr)
EP (2) EP1960429B1 (fr)
JP (1) JP5015949B2 (fr)
KR (1) KR101355118B1 (fr)
CN (1) CN101374863B (fr)
AR (1) AR057239A1 (fr)
AU (1) AU2006325228B2 (fr)
BR (1) BRPI0619855A2 (fr)
CA (1) CA2633501C (fr)
CR (1) CR10099A (fr)
CY (1) CY1113094T1 (fr)
DK (1) DK1960429T3 (fr)
EA (1) EA015536B1 (fr)
ES (1) ES2389380T3 (fr)
GB (1) GB0525662D0 (fr)
HR (1) HRP20120684T1 (fr)
IL (1) IL192086A0 (fr)
JO (1) JO2795B1 (fr)
MA (1) MA30041B1 (fr)
MY (1) MY149492A (fr)
NO (1) NO20082699L (fr)
NZ (1) NZ569143A (fr)
PE (1) PE20071099A1 (fr)
PL (1) PL1960429T3 (fr)
PT (1) PT1960429E (fr)
SI (1) SI1960429T1 (fr)
TW (1) TWI378940B (fr)
UA (1) UA96279C2 (fr)
WO (1) WO2007068750A2 (fr)
ZA (2) ZA200805111B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2704357C (fr) * 2007-11-02 2016-06-21 Novartis Ag Molecules ameliorees de liaison a nogo-a et utilisation pharmaceutique de celles-ci
CN106349390B (zh) 2008-04-02 2019-12-10 宏观基因有限公司 Bcr-复合体-特异性抗体和其使用方法
PE20091964A1 (es) 2008-05-06 2010-01-09 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos
CA2730473A1 (fr) * 2008-07-11 2010-01-14 Glaxo Group Limited Traitement inedit
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
IN2014KN02952A (fr) 2012-07-05 2015-05-08 Glaxo Group Ltd
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
US11013815B2 (en) 2017-06-14 2021-05-25 Monojul, Llc High-affinity anti-human folate receptor beta antibodies and methods of use
JP7617040B2 (ja) * 2019-06-13 2025-01-17 プレステージ バイオファーマ リミテッド Ｃｔｈｒｃ１に特異的な新規抗体及びその使用
BR112022006534A2 (pt) * 2019-10-24 2022-07-05 Novago Therapeutics Ag Anticorpos anti-nogo-a
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
WO2022263864A1 (fr) 2021-06-17 2022-12-22 Petmedix Ltd Anticorps anti-cd20 canin
MX2024004875A (es) 2021-10-21 2024-07-19 Petmedix Ltd Proteinas que comprenden en el dominio extracelular de p75ntr.
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
WO2023152486A1 (fr) 2022-02-09 2023-08-17 Petmedix Ltd Anticorps thérapeutiques
WO2024041450A1 (fr) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 Anticorps pour reconnaître de manière spécifique nogo-a et son utilisation
GB202217993D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Therapeutic antibodies
CN120712277A (zh) 2023-02-09 2025-09-26 佩特迈迪有限公司 包含p75神经营养因子受体(p75ntr)胞外结构域变体的治疗分子
WO2026041734A1 (fr) 2024-08-22 2026-02-26 Novago Therapeutics Ag Méthodes de traitement de troubles neurologiques utilisant des anticorps anti-nogo-a

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
DE69531458T2 (de) 1994-05-27 2004-08-05 Glaxosmithkline S.P.A. Chinolinderivate als tachykinin nk3 rezeptor antagonisten
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5932542A (en) 1995-06-27 1999-08-03 Research Foundation Of Cuny, Hunter College Composition and methods using myelin-associated glycoprotein (MAG) and inhibitors thereof
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
JP2002522016A (ja) 1998-07-22 2002-07-23 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 神経内分泌特異的タンパク質に類似したタンパク質、およびそれをコードするｃＤＮＡ
SK287323B6 (sk) 1998-11-06 2010-07-07 University Of Z�Rich Nogo proteín, jeho purifikovaný fragment, chimérny proteín a purifikovaná molekula s jeho obsahom, izolovaná nukleová kyselina, vektor s jej obsahom, rekombinantná bunka, spôsob produkcie rekombinantného proteínu a jeho použitie
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
DE10338136A1 (de) 2003-08-15 2005-03-24 European Molecular Biology Laboratory Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
NZ548013A (en) * 2003-12-22 2009-04-30 Glaxo Group Ltd Immunoglobulins
US7981843B2 (en) * 2004-01-20 2011-07-19 Kalobios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
EP1786463A4 (fr) * 2004-03-26 2009-05-20 Human Genome Sciences Inc Anticorps contre le recepteur nogo

Also Published As

Publication number Publication date
JO2795B1 (en) 2014-03-15
CY1113094T1 (el) 2016-04-13
CN101374863B (zh) 2013-05-29
CA2633501A1 (fr) 2007-06-21
EA200801343A1 (ru) 2008-12-30
DK1960429T3 (da) 2012-09-24
EA015536B1 (ru) 2011-08-30
EP1960429A2 (fr) 2008-08-27
JP2009519025A (ja) 2009-05-14
EP2228391A3 (fr) 2010-12-29
ZA200805111B (en) 2009-12-30
KR20080080644A (ko) 2008-09-04
PL1960429T3 (pl) 2012-11-30
AU2006325228B2 (en) 2011-12-15
EP1960429B1 (fr) 2012-06-27
HRP20120684T1 (hr) 2012-09-30
TW200801038A (en) 2008-01-01
HK1119720A1 (en) 2009-03-13
US20100221260A1 (en) 2010-09-02
CN101374863A (zh) 2009-02-25
UA96279C2 (ru) 2011-10-25
EP2228391A2 (fr) 2010-09-15
AU2006325228A1 (en) 2007-06-21
CA2633501C (fr) 2015-03-31
US8362208B2 (en) 2013-01-29
AR057239A1 (es) 2007-11-21
ZA200906162B (en) 2010-05-26
NO20082699L (no) 2008-09-08
IL192086A0 (en) 2008-12-29
JP5015949B2 (ja) 2012-09-05
MY149492A (en) 2013-09-13
ES2389380T3 (es) 2012-10-25
WO2007068750A3 (fr) 2007-11-29
NZ569143A (en) 2011-08-26
BRPI0619855A2 (pt) 2011-10-25
WO2007068750A2 (fr) 2007-06-21
PT1960429E (pt) 2012-09-25
GB0525662D0 (en) 2006-01-25
US20130287781A1 (en) 2013-10-31
KR101355118B1 (ko) 2014-02-06
CR10099A (es) 2008-09-22
SI1960429T1 (sl) 2012-09-28
PE20071099A1 (es) 2007-11-22
TWI378940B (en) 2012-12-11

Similar Documents

Publication Publication Date Title
MA28289A1 (fr) Immunoglobulines
MA33381B1 (fr) Proteine de liaison a il-13
WO2004024097A8 (fr) Compositions et methodes de traitement de maladies de nature immune
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
MA30340B1 (fr) Nouveaux composes
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA30462B1 (fr) Composes de pyridylamide antagonistes des canaux calciques de type t
TNSN04268A1 (fr) UTILISATION D'INHIBITEURS CETP ET FACULTATIVEMENT D'INHIBITEURS DE HMG -CoA - REDUCTASE ET/OU D'AGENTS ANTI-HYPERTENSIFS
MA30962B1 (fr) Anticorps antifacteurs d'humanisés et leurs utilisations.
MA27675A1 (fr) Derives de piperazine et leur utilisation dans le traitement de maladies neurologiques et psychiatriques
MA29931B1 (fr) Inhibiteurs de la proteine d'activation de la 5-lipoxygenase (flap)
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
MA27668A1 (fr) 2,4-di(phenylamino) pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire
MA31312B1 (fr) Anticorps anti-ige apoptopiques
MA32804B1 (fr) Antagonistes d'isonicotinamide des récepteurs de l'orexine
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA31845B1 (fr) Pipéridino-dihydrothiénopyrimidines substituées
EP2101757A4 (fr) Composé pour le traitement ou la prévention de maladies en relation avec la prostate et compositions pharmaceutiques de système d'administration par le colon contenant ce composé
MA29625B1 (fr) Immunoglobulines
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
EP1711197A4 (fr) Methodes et compositions pour la prevention et le traitement de maladies ou de troubles inflammatoires
MA27794A1 (fr) Dihydroquinazolines substituees a proprietes antivirales
MA67288A1 (fr) Tubulysines et conjugués tubulysines-protéines